SANOFI'S IMMUNOLOGY PIPELINE


Associated tags: Patient, Congress, Conjunctivitis, Psoriasis Area and Severity Index, Atopic dermatitis, European Academy of Allergy and Clinical Immunology, Journal of the European Academy of Dermatology and Venereology, Disease, IGA, Vaccine, Dermatology, Venereology, EASI

Press Release: Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis

Retrieved on: 
Friday, October 13, 2023
Congress, Conjunctivitis, Psoriasis Area and Severity Index, Atopic dermatitis, European Academy of Allergy and Clinical Immunology, Journal of the European Academy of Dermatology and Venereology, Patient, Disease, IGA, Vaccine, Dermatology, Venereology, EASI

The Phase 3 program for amlitelimab in atopic dermatitis is on track to start in the first half of 2024.

Key Points: 
  • The Phase 3 program for amlitelimab in atopic dermatitis is on track to start in the first half of 2024.
  • Global Head of Research & Development, Sanofi
    “The data presented at EADV provide more detailed insight into amlitelimab’s potential as a best-in-class therapy for people with atopic dermatitis.
  • TEAEs more commonly observed with amlitelimab compared to placebo included nasopharyngitis (11.0% amlitelimab, 9.0% placebo), COVID-19 (7.7% amlitelimab, 6.4% placebo) and headache (6.1% amlitelimab, 2.6% placebo).
  • Worsening of atopic dermatitis was more commonly observed with placebo compared to amlitelimab (38.5% placebo, 17.1% amlitelimab).